Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2937637 | 0.83 | HTT (0.48) | HTTGAAADORA1LMNANPC1 | |
| SCHEMBL10051192 | 0.74 | NOS3 (0.43) | HTTADORA1LMNANPC1RAB9A | |
| SCHEMBL10272807 | 0.74 | SLC6A3 (0.48) | HTTLMNANPC1RAB9ATSHR | |
| SCHEMBL4288745 | 0.73 | HTT (0.41) | HTTGAAADORA1LMNANPC1 | |
| SCHEMBL2632758 | 0.73 | HTT (0.44) | HTTGAAADORA1LMNANPC1 | |
| Ammonia Solution, Strong SCHEMBL27633883 | 0.73 | NOS3 (0.42) | HTTADORA1LMNANPC1RAB9A | |
| SCHEMBL18011660 | 0.73 | NOS2 (0.48) | HTTNPC1RAB9AMAPT | |
| SCHEMBL29826849 | 0.73 | HTT (0.44) | HTTGAAADORA1LMNANPC1 | |
| SCHEMBL29957984 | 0.72 | HTT (0.37) | HTTADORA1LMNAMAPTKDM4E | |
| SCHEMBL12440999 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144741-A1 | ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS | FREDERIKSEN MATHIAS | 2010-06-10 | — | — | US | disclosed |
| US-20100144741-A1 | ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS | FREDERIKSEN MATHIAS | 2010-06-10 | — | — | US | disclosed |
| WO-2008062044-A1 | 2-HYDROXY-1,3-DIAMINOPROPANE DERIVATIVES | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144741-A1 | ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | HTT 2542/4885GAA 60/4885ADORA1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.